Claims

1. Use of a ω-3 polyunsaturated fatty acid in the manufacture of a drug, a preparation or a device for regulating eye scleral lipid metabolism in an individual.

2. The use according to claim 1, wherein the device is an instrument, equipment, a consumable, system, a medical device, a health care product or an eye appearance-altering product that can release a drug or has a drug delivery function or has a potential of delivering drugs, or

the device is various glasses, as well as instruments, equipment, consumables, medical instruments or health care products that have a vision protecting function or a myopia treatment (correction) effect.

3. The use according to claim 1 or 2, wherein the preparation is an oral product, a health care product, food, a dietary supplement, a nutritional product, or a cosmetic.

4. The use according to claim 1 or 2, wherein the drug or the preparation is an injection, a tablet, a lyophilized powder injection, a capsule, an effervescent tablet, a chewable tablet, a buccal tablet, a granule, an ointment, a syrup, an oral liquid, an aerosol, a nasal drop, an external preparation, or an ophthalmic dosage form.

5. The use according to claim 4, wherein ophthalmic dosage form including but not limited to an eye drop, an eye ointment, an eye spray, an implant, an ophthalmic gel, an eye patch, an ophthalmic microsphere, an ophthalmic sustained-release preparation, a periocular injection, or an intraocular injection.

6. The use according to claims 1 or 2, wherein the drug, the preparation or the device also comprises other ophthalmic preparations or drugs, including but not limited to drugs for treating myopia, M receptor blockers, dibazole, polyunsaturated fatty acids, salidroside, prazosin, homatropine, anisodamine (racemic), topicamide, 7-methyl xanthine, nicotinic acid, Piracetam, a red sage root extract, a safflower extract, fish oil, a bear bile extract, vitamins, ATP, and adjuvants for ophthalmic diseases.

7. The use according to claims 1 or 2, wherein the ω-3 polyunsaturated fatty acid is DHA alone or a composition of DHA and EPA.

8. Use of a substance for regulating eye scleral lipid metabolism in the manufacture of a drug, a preparation or a device for preventing, delaying, inhibiting

and/or treating myopia and myopia-related diseases, wherein the substance for regulating eye scleral lipid metabolism is a ω-3 polyunsaturated fatty acid, wherein the ω-3 polyunsaturated fatty acid is a composition of DHA and EPA, in the composition of DHA and EPA, EPA is a predominant component, EPA:DHA > 1: 1.

9. The use according to claim 8, wherein the device is an instrument, equipment, a consumable, a system, a medical device, a health care product or an eye appearance-altering product that can release a drug or has a drug delivery function or has a potential of delivering drugs, or

the device is various glasses, as well as instruments, equipment, consumables, medical instruments or health care products that have a vision protecting function or a myopia treatment (correction) effect.

10. The use according to claims 8 or 9, wherein the preparation is an oral product, a health care product, food, a dietary supplement, a nutritional product, or a cosmetic.

11. The use according to claims 8 or 9, wherein the drug or the preparation is an injection, a tablet, a lyophilized powder injection, a capsule, an effervescent tablet, a chewable tablet, a buccal tablet, a granule, an ointment, a syrup, an oral liquid, an aerosol, a nasal drop, an external preparation, or an ophthalmic dosage form.

12. The use according to claims 11, wherein ophthalmic dosage form including but not limited to an eye drop, an eye ointment, an eye spray, an implant, an ophthalmic gel, an eye patch, an ophthalmic microsphere, an ophthalmic sustained-release preparation, a periocular injection, or an intraocular injection.

13. The use according to claims 8 or 9, wherein the drug, preparation or device also comprises other ophthalmic preparations or drugs, including but not limited to drugs for treating myopia, M receptor blockers, dibazole, polyunsaturated fatty acids, salidroside, prazosin, homatropine, anisodamine (racemic), topicamide, 7-methyl xanthine, a nicotinic acid, Piracetam, a red sage root extract, a safflower extract, fish oil, a bear bile extract, vitamins, ATP, and adjuvants for ophthalmic diseases.

14. The use according to claims 8 or 9, wherein the myopia is refractive myopia and/or axial myopia; congenital myopia, early-onset myopia, delayed myopia, late-onset myopia; low myopia, moderate myopia, high myopia; pseudomyopia, true myopia, myopia in minors, myopia in adults, and myopia in the elderly; simple myopia, and pathological myopia; primary myopia, secondary myopia or progressive myopia.

15. The use according to claims 8 or 14, wherein people involved in the myopia refer to people whose eyes are still in the stage of growth and development.

16. A drug, preparation or device for regulating eye scleral lipid metabolism, comprising a ω-3 polyunsaturated fatty acid, wherein the ω-3 polyunsaturated fatty acid is a composition of DHA and EPA, in the composition of DHA and EPA, EPA is a predominant component, EPA:DHA > 1: 1.

17. The drug, preparation or device according to claim 16, wherein the drug or the preparation is an injection, a tablet, a lyophilized powder injection, a capsule, an effervescent tablet, a chewable tablet, a buccal tablet, a granule, an ointment, a syrup, an oral liquid, an aerosol, a nasal drop, an external preparation, or an ophthalmic dosage form.

18. The drug, preparation or device according to claim 17, wherein ophthalmic dosage form including but not limited to an eye drop, an eye ointment, an eye spray, an implant, an ophthalmic gel, an eye patch, an ophthalmic a microsphere, an ophthalmic sustained-release preparation, a periocular injection, or an intraocular injection.